SAB Biotherapeutics, Inc. (SABSW) stock
SABSWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SABS
$0.01+0.00 (+33.33%)
Close on Oct 20, 2026Market cap $304.80MP/E –Yield –
SAB Biotherapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
SAB Biotherapeutics's operating income for the twelve months ending Jun 30, 2026 was -$71.82M. For fiscal 2025 it was -$48.95M. The highest annual figure on record is $20.56M in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$48.95M | – |
| FY2024 | Dec 31, 2024 | -$42.91M | – |
| FY2023 | Dec 31, 2023 | -$38.08M | – |
| FY2022 | Dec 31, 2022 | -$28.92M | – |
| FY2021 | Dec 31, 2021 | -$13.39M | -165.2% |
| FY2020 | Dec 31, 2020 | $20.56M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$23.38M | – |
| Q1 FY2026 | Mar 31, 2026 | -$20.00M | – |
| Q4 FY2025 | Dec 31, 2025 | -$15.77M | – |
| Q3 FY2025 | Sep 30, 2025 | -$12.68M | – |
| Q2 FY2025 | Jun 30, 2025 | -$9.73M | – |
| Q1 FY2025 | Mar 31, 2025 | -$10.77M | – |
| Q4 FY2024 | Dec 31, 2024 | -$10.01M | – |
| Q3 FY2024 | Sep 30, 2024 | -$11.31M | – |
| Q2 FY2024 | Jun 30, 2024 | -$10.20M | – |
| Q1 FY2024 | Mar 31, 2024 | -$11.39M | – |
| Q4 FY2023 | Dec 31, 2023 | -$18.87M | – |
| Q3 FY2023 | Sep 30, 2023 | -$5.32M | – |
| Q2 FY2023 | Jun 30, 2023 | -$6.48M | – |
| Q1 FY2023 | Mar 31, 2023 | -$7.40M | – |
| Q4 FY2022 | Dec 31, 2022 | -$7.86M | – |
| Q3 FY2022 | Sep 30, 2022 | -$7.81M | – |
| Q2 FY2022 | Jun 30, 2022 | -$6.54M | – |
| Q1 FY2022 | Mar 31, 2022 | -$6.71M | -924.1% |
| Q4 FY2021 | Dec 31, 2021 | -$7.34M | – |
| Q3 FY2021 | Sep 30, 2021 | -$3.99M | – |
| Q2 FY2021 | Jun 30, 2021 | -$2.87M | – |
| Q1 FY2021 | Mar 31, 2021 | $813.92K | – |